321 related articles for article (PubMed ID: 27995810)
1. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
[TBL] [Abstract][Full Text] [Related]
2. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
5. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
6. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
7. Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review.
Sargazi S; Mukhtar M; Rahdar A; Barani M; Pandey S; Díez-Pascual AM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638660
[TBL] [Abstract][Full Text] [Related]
8. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
11. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
12. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship.
Das PK; Matada GSP; Pal R; Maji L; Dhiwar PS; Manjushree BV; Viji MP
Eur J Med Chem; 2024 Aug; 274():116535. PubMed ID: 38838546
[TBL] [Abstract][Full Text] [Related]
14. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
Wang Q; Zhang J
Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
[TBL] [Abstract][Full Text] [Related]
15. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
16. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Mégnin-Chanet F; Bollet MA; Hall J
Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
[TBL] [Abstract][Full Text] [Related]
17. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
18. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
AlGhamdi A; AlMubayedh H
Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]